MiniMed initiated with a Neutral at Piper Sandler

Piper Sandler analyst Matt O’Brien initiated coverage of MiniMed (MMED) with a Neutral rating and $16 price target MiniMed is a diabetes provider with a “significant” international presence, operating as the market leader in several large markets, the analyst tells investors in a research note. Piper believes the company is behind its competitors from a form factor and ease-of-use perspective. It believes this could hurt MiniMed’s growth and put estimates at risk over the next several years.